77 results on '"Pericarditis prevention & control"'
Search Results
2. Safety and Efficacy of Colchicine for the Prevention of Pericarditis in Patients Who Underwent Catheter Ablation for Atrial Fibrillation.
- Author
-
Agarwal S, Hashim L, Po S, and Asad ZUA
- Subjects
- Humans, Colchicine therapeutic use, Treatment Outcome, Recurrence, Atrial Fibrillation complications, Atrial Fibrillation surgery, Pericarditis prevention & control, Catheter Ablation
- Abstract
Competing Interests: Declaration of Competing Interest The authors have no competing interests to declare.
- Published
- 2023
- Full Text
- View/download PDF
3. Is Colchicine Useful to Prevent Post-AF Ablation Pericarditis?: A Question in Search of an Answer.
- Author
-
Raviele A
- Subjects
- Humans, Colchicine therapeutic use, Pericarditis drug therapy, Pericarditis prevention & control, Pericarditis surgery, Atrial Fibrillation surgery, Catheter Ablation adverse effects
- Abstract
Competing Interests: Funding Support and Author Disclosures The author has reported that he has no relationships relevant to the contents of this paper to disclose.
- Published
- 2023
- Full Text
- View/download PDF
4. Prophylactic Colchicine After Radiofrequency Ablation of Atrial Fibrillation: The PAPERS Study.
- Author
-
Ahmed AS, Miller J, Foreman J, Golden K, Shah A, Field J, Gilge J, Clark B, Joshi S, Nair G, Olson J, Padanilam BJ, Prystowsky E, and Patel PJ
- Subjects
- Humans, Colchicine adverse effects, Prospective Studies, Treatment Outcome, Neoplasm Recurrence, Local etiology, Atrial Fibrillation drug therapy, Atrial Fibrillation surgery, Atrial Fibrillation etiology, Catheter Ablation adverse effects, Catheter Ablation methods, Pericarditis epidemiology, Pericarditis prevention & control, Pericarditis complications
- Abstract
Background: Pericarditis is common after radiofrequency ablation for atrial fibrillation (AF)., Objectives: Study investigators hypothesized an empirical post-AF ablation treatment protocol with colchicine may reduce the incidence and severity of pericarditis. PAPERS (Post-Ablation PEricarditis Reduction Study) aimed to quantify the risks and benefits associated with prophylactic use of colchicine to prevent pericarditis following AF ablation., Methods: PAPERS is a multicenter, prospective, randomized controlled study. Patients were randomized on the day of the procedure to receive no postprocedure prophylaxis (group A; standard of care arm) or colchicine 0.6 mg orally twice daily for 7 days starting immediately post-procedure (group B; study arm). All participants underwent a follow-up survey at 14 days postoperatively. The primary endpoint was the development of clinical pericarditis within 2 weeks following ablation. Secondary outcomes included the incidence of pericarditis by ablation type and medical therapy., Results: Among 139 patients enrolled, 66 were randomized to standard of care (group A), and 73 patients were randomized to the colchicine arm (group B). The primary outcome of clinical pericarditis was reached in 7 of 66 (10.6%) patients in group A and in 7 of 73 (9.6%) patients in group B (P = 0.84). The rate of gastrointestinal discomfort was 10 of 66 (15%) in group A and 34 of 73 (47%) in group B (P < 0.001). There was an increased incidence of pericarditis in patients who underwent cavotricuspid isthmus ablation (17 of 50; 34%) in addition to pulmonary vein isolation (6 of 69; 8.7%; P = 0.001)., Conclusions: Prophylactic colchicine therapy initiated after the ablation procedure in patients with AF did not affect the incidence of post-ablation pericarditis and was associated with an increased incidence of gastrointestinal side effects., Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
5. Colchicine usage for prevention of post atrial fibrillation ablation pericarditis in patients undergoing high-power short-duration ablation.
- Author
-
Iqbal AM, Li KY, and Gautam S
- Subjects
- Humans, Colchicine adverse effects, Retrospective Studies, Treatment Outcome, Diarrhea drug therapy, Diarrhea etiology, Diarrhea surgery, Chest Pain surgery, Recurrence, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Atrial Fibrillation drug therapy, Pericardial Effusion diagnosis, Pericardial Effusion epidemiology, Pericardial Effusion etiology, Pericarditis diagnosis, Pericarditis prevention & control, Pericarditis epidemiology, Catheter Ablation adverse effects, Catheter Ablation methods, Pulmonary Veins surgery
- Abstract
Introduction: Radiofrequency ablation (RFA) for atrial fibrillation (AF) has been associated with variable incidence (0.88%-10%) of pericarditis manifested as chest pain, possibly more prevalent with the advent of high-power short-duration (HPSD) ablation. This has led to the widespread use of colchicine in preventative protocols for postablation pericarditis. However, the efficacy of preventative colchicine has not been validated yet., Objective: To evaluate the efficacy of a routine postoperative colchicine regimen (0.6 mg twice a day for 14 days post-AF ablation) for prevention of postablation pericarditis in patients undergoing HPSD ablation., Method: We retrospectively evaluated consecutive single-operator HPSD AF ablation procedures at our institution from June 2019 to July 2022. A colchicine protocol was introduced in June 2021 for the prevention of postablation pericarditis. All ablations were performed with 50 watts. Patients were divided into colchicine and noncolchicine groups. We recorded incidence of postablation chest pain, emergency room (ER) visit for chest pain, pericardial effusion, pericardiocentesis, any ER visit, hospitalization, AF recurrence, and cardioversion for AF within the first 30 days following ablation. We also recorded colchicine-related side effects and medication compliance., Results: Two hundred and ninety-four consecutive HPSD AF ablation patients were screened for the study. After implementing the prespecified exclusion criteria, a total of 205 patients were included in the final analysis, yielding 101 patients in the colchicine group and 104 patients in the noncolchicine group. Both groups were well-matched for demographic and procedural parameters. There was no significant difference in postablation chest pain (9.9% vs. 8.6%, p = .7), pericardial effusion (2.9% vs. 0.9%, p = .1), ER visits (11.9% vs. 12.5%, p = .2), 30-day hospitalization for AF recurrence (0.9% vs. 0.96%, p = .3), and 30-day need for cardioversion for AF (3.9% vs. 5.7%, p = .2). Fifteen (15) patients had severe colchicine-related diarrhea, out of which 12 discontinued it prematurely. There were no major procedural complications in either group., Conclusion: In this single-operator retrospective analysis, prophylactic colchicine was not associated with significant reduction in the incidence of postablation chest pain, pericarditis, 30 day hospitalization, ER visits, or AF recurrence or need of cardioversion within first 30 days after HPSD ablation for AF. However, its usage was associated with significant diarrhea. This study concludes no additional advantage of prophylactic use of colchicine after HPSD AF ablation., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
6. Could Amifostine Prevent Experimental Radiotherapy-Induced Acute Pericarditis?
- Author
-
Bahat Z, Cobanoglu U, Ulku C, Kalyoncu Nİ, Caner Karahan S, and Yavuz MN
- Subjects
- Animals, Antioxidants, Inflammation drug therapy, Rats, Saline Solution, Amifostine pharmacology, Amifostine therapeutic use, Pericarditis drug therapy, Pericarditis etiology, Pericarditis prevention & control, Radiation Injuries drug therapy, Radiation Injuries etiology, Radiation Injuries prevention & control, Radiation-Protective Agents pharmacology
- Abstract
Background: Amifostine is a powerful antioxidant that is one of the documented three chemo-radio prototectants recommended for clinical use. There is no data exploring amifostine in prevention of acute pericardial damage. We aimed to investigate whether amifostine has protective effect against acute pericardial injury due to radiotherapy in an experimental rat model., Methods: Twenty-four rats were divided into four groups: control group, radiotherapy-only group, amifostine-only group, radiotherapy+amifostine group. In groups receiving radiotherapy, hearts were irradiated with a Co 60 teletherapy device at a distance of 80 cm and 20 Gy at a depth of 2 cm. Thirty minutes before interventions, 200 mg/kg amifostine or same volume 0.9% NaCl were administered intraperitoneally. Subjects were sacrificed 24 hours after the procedure. Pericardial histopathological changes were investigated by light microscopy., Results: There was focal inflammation of >= 50% in all rats exposed-to-radiotherapy. All groups receiving radiotherapy revealed a significant increase in pericardial inflammation compared to the groups that did not receive irradiation (p<0.05). There was no difference between the radiotherapy-only group and amifostine+radiotherapy group for pericardial inflammatory response (p>0.05)., Conclusion: Acute pericarditis was detected in all rats receiving radiotherapy. There was no positive effect of amifostine administration before radiotherapy on acute pericardial inflammation.
- Published
- 2022
- Full Text
- View/download PDF
7. The IL-1 trap rilonacept resolves and prevents recurrent pericarditis.
- Author
-
Fernández-Ruiz I
- Subjects
- Humans, Interleukin-1, Recombinant Fusion Proteins, Pericarditis drug therapy, Pericarditis prevention & control
- Published
- 2021
- Full Text
- View/download PDF
8. Radiation-Associated Pericardial Disease.
- Author
-
Szpakowski N and Desai MY
- Subjects
- Cardiotoxicity etiology, Cardiotoxicity prevention & control, Cardiotoxicity therapy, Dose-Response Relationship, Radiation, Humans, Neoplasms radiotherapy, Pericardial Effusion etiology, Pericardial Effusion prevention & control, Pericardial Effusion therapy, Pericarditis etiology, Pericarditis prevention & control, Pericarditis therapy, Pericardium injuries, Pericardium radiation effects, Radiation Injuries diagnostic imaging, Radiation Injuries etiology, Radiation Injuries prevention & control, Radiation Injuries therapy, Risk Factors, Cardiotoxicity diagnostic imaging, Pericardial Effusion diagnostic imaging, Pericarditis diagnostic imaging, Pericardium diagnostic imaging
- Abstract
Purpose of Review: This review highlights the literature related to pericardial injury following radiation for oncologic diseases., Recent Findings: Radiation-associated pericardial disease can have devastating consequences. Unfortunately, there is considerably less evidence regarding pericardial syndromes following thoracic radiation as compared to other cardiovascular outcomes. Pericardial complications of radiation may arise acutely or have an insidious onset several decades after treatment. Transthoracic echocardiography is the screening imaging modality of choice, while cardiac magnetic resonance imaging further characterizes the pericardium and guides treatment decision-making. Cardiac CT can be useful for assessing pericardial calcification. Ongoing efforts to lessen inadvertent cardiac injury are directed towards the revision of radiation techniques and protocols. As survival of mediastinal and thoracic malignancies continues to improve, radiation-associated pericardial disease is increasingly relevant. Though advances in radiation oncology demonstrate promise in curtailing cardiotoxicity, the long-term effects pertaining to pericardial complications remain to be seen.
- Published
- 2019
- Full Text
- View/download PDF
9. Acupuncture-Related Cardiac Complications: A Systematic Review.
- Author
-
Ullah W, Ahmad A, Mukhtar M, Virk HUH, Sarwar U, and Figueredo V
- Subjects
- Acupuncture Therapy methods, Humans, Risk Adjustment, Risk Factors, Acupuncture Therapy adverse effects, Cardiac Tamponade etiology, Cardiac Tamponade prevention & control, Endocarditis etiology, Endocarditis prevention & control, Heart Rupture etiology, Heart Rupture prevention & control, Pericarditis etiology, Pericarditis prevention & control
- Abstract
Background: The objective of this study is to review acupuncture-related cardiac complications, such as infective endocarditis (IE), cardiac tamponade (CT), pericarditis, and cardiac rupture, as there is no known reported literature to determine the burden of cardiac adverse events due to acupuncture., Methods: Structured computerized databases were searched using the special Medical Subject Heading (MeSH). Manual search using the references of relevant articles was also performed., Results: A total of 133 articles were initially retrieved, but careful reading resulted in only 30 cases of relevant cardiac adverse events. There were 8 articles of infective complications (mostly IE), while 22 articles of CT have been reported to date. The diagnoses were made with echocardiography and patients were treated with intravenous antibiotics. The source of the infection was mostly localized to acupuncture needle prick sites, such as earlobes and legs. Mortality rate for post-acupuncture CT was not significantly higher than infective cardiac complication (Pearson's Chi-square = 0.559; likelihood ratio = 0.553). However, the weighted percentage of death was about 80% in CT vs only 20% mortality for infective cardiac complications. On the other hand, CT was the most common presentation when the needle pricks were close to the heart, and had a clinical presentation of hypotension and venous distention., Conclusions: Although the universally reported complications of acupuncture are low, and the procedure itself has been deemed low risk in acupuncture-related literature, these cardiac complications are alarming. To avoid these potentially catastrophic consequences, more education needs to be done for adopting safer techniques.
- Published
- 2019
10. Duration of immunity for an inactivated Mycoplasma hyorhinis vaccine in pigs.
- Author
-
Martinson B, Zoghby W, Barrett K, Bryson L, and Kroll J
- Subjects
- Animals, Arthritis prevention & control, Bacterial Vaccines administration & dosage, Female, Lung immunology, Lung microbiology, Male, Mycoplasma Infections immunology, Mycoplasma Infections prevention & control, Pericarditis prevention & control, Swine immunology, Swine microbiology, Swine Diseases immunology, Vaccination, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, Arthritis veterinary, Bacterial Vaccines immunology, Mycoplasma Infections veterinary, Mycoplasma hyorhinis immunology, Pericarditis veterinary, Swine Diseases prevention & control
- Abstract
Mycoplasma hyorhinis (Mhr) is a pathogen of pigs causing polyserositis and polyarthritis. The most susceptible population are nursery pigs of approximately 7 weeks of age, although we have shown that clinical signs can persist into finishing aged animals after a late-nursery infection. We have previously demonstrated the efficacy of a novel inactivated Mhr vaccine for the reduction of lameness and polyserositis in caesarian-derived colostrum-deprived (CDCD) pigs vaccinated at 3 weeks and challenged with Mhr at 6 weeks of age. Here we evaluated the duration of immunity (DOI) of the same vaccine. Vaccine or placebo was administered to CDCD pigs at 3 weeks of age. Pigs were challenged with Mhr at either 10 weeks of age (=7 week DOI) or 13 weeks of age (=10 week DOI). In the 7 week DOI, vaccination provided significant reductions in lameness (p = 0.0018), arthritis (p = 0.0002), and pericarditis (p = 0.0312) versus the placebo control. In the 10 week DOI, a significant reduction in arthritis (p = 0.0320) was observed in the vaccine group as compared to the placebo group. Both vaccine groups showed a significant increase (p < 0.0001) in the post-challenge average daily gain (ADG), gaining 0.2 kg/day more than their respective placebo groups., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
11. Colchicine in addition to conventional therapy for pericarditis recurrence : An update meta-analysis.
- Author
-
Li YL, Qiao SB, Wang JY, Chen YM, Luo J, and Zhang HF
- Subjects
- Aged, Anti-Inflammatory Agents administration & dosage, Drug Combinations, Female, Humans, Male, Middle Aged, Pericarditis diagnosis, Pericarditis drug therapy, Prevalence, Recurrence, Risk Factors, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Colchicine administration & dosage, Pericarditis epidemiology, Pericarditis prevention & control, Prednisone administration & dosage
- Abstract
Background: Randomized controlled trials (RCTs) have investigated the use of colchicine and conventional therapy for reducing the recurrence of pericarditis in patients with acute pericarditis or post-pericardiotomy syndrome. However, the benefits of these treatments are variable., Methods: Studies were retrieved from PubMed, the Cochrane Library, and the EMBASE database., Results: We identified nine RCTs with 1832 patients and a mean follow-up of 13.1 months. Overall, colchicine therapy significantly decreased the risk of pericarditis recurrence (odds ratio, OR 0.42; 95 % confidence interval, CI 0.33-0.52; P < 0.001; I
2 = 17.0 %). Colchicine therapy was associated with significantly lower rates of pericarditis-associated rehospitalization (OR 0.29; 95 % CI 0.16-0.53; P < 0.0001; I2 = 0.0 %) and persistence of symptoms (OR 0.29; 95 % CI, 0.21-0.41; P = 0.000; I2 = 0.0 %) at 72 h. Adverse events were higher in the colchicine group (relative risk, RR 1.48; 95 % CI, 1.06-2.07; P = 0.02; I2 = 0.0 %). Subgroup analysis showed that recurrence of pericarditis was significantly lower in the colchicine therapy group, irrespective of prednisone use and the cause of pericarditis., Conclusion: Colchicine significantly decreases the rate of pericarditis recurrence, regardless of prednisone use and the cause of pericarditis. Larger studies are needed to confirm this effect.- Published
- 2016
- Full Text
- View/download PDF
12. Effect of colchicine in prevention of pericardial effusion and atrial fibrillation: a meta-analysis.
- Author
-
Wang MX, Deng XL, Mu BY, Cheng YJ, Chen YJ, Wang Q, Huang J, Zhou RW, and Huang CB
- Subjects
- Atrial Fibrillation drug therapy, Cardiac Surgical Procedures adverse effects, Cardiac Surgical Procedures statistics & numerical data, Chi-Square Distribution, Colchicine therapeutic use, Humans, Pericardial Effusion drug therapy, Pericarditis drug therapy, Pericarditis prevention & control, Recurrence, Atrial Fibrillation prevention & control, Colchicine pharmacology, Pericardial Effusion prevention & control
- Abstract
Randomized, controlled trials (RCTs) have assessed the effect of colchicine therapy in prevention of pericardial effusion (PE) and atrial fibrillation (AF). However, the effects are still inconclusive. PubMed, Cochrane Library, Google Scholar, and EMBASE database were searched. Primary outcome was the risk of PE and AF. Ten RCTs with 1981 patients and a mean follow-up of 12.6 months were included. Colchicine therapy was not associated with a significantly lower risk of post-operative PE (RR, 0.89; 95 % CI 0.70-1.13; p = 0.33, I (2) = 72.8 %) and AF (RR, 0.77; 95 % CI 0.52-1.13; p = 0.18, I (2) = 47.3 %). However, rates of pericarditis recurrence, symptoms persistence, and pericarditis-related hospitalization were significantly decreased with colchicine treatment. In addition, cardiac tamponade occurrence was similar between groups, and adverse events were significantly higher in the colchicine group. Colchicine may not significantly decrease the post-operative risk of PE and AF. However, only limited studies about patients undergoing cardiac surgery provide data about PE and AF.
- Published
- 2016
- Full Text
- View/download PDF
13. BET 1: Safety and efficacy of colchicine as stand-alone therapy for the prevention of recurrent pericarditis.
- Author
-
Manspeaker A and Andrews-Dickert R
- Subjects
- Humans, Recurrence, Colchicine therapeutic use, Pericarditis prevention & control, Secondary Prevention, Tubulin Modulators therapeutic use
- Abstract
A short cut review was carried out looking for evidence of the benefits of using colchicine as a single therapy for acute pericarditis. A literature search was performed but no papers were found to provide evidence of the efficacy of colchicine without the concurrent use of Non-steriodal anti-inflammatory drugs (NSAIDs) for this condition., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
14. Impact of Periprocedural Colchicine on Postprocedural Management in Patients Undergoing a Left Atrial Appendage Ligation Using LARIAT.
- Author
-
Gunda S, Reddy M, Nath J, Nagaraj H, Atoui M, Rasekh A, Ellis CR, Badhwar N, Lee RJ, DI Biase L, Mansour M, Ruskin JN, Natale A, Earnest M, and Lakkireddy DR
- Subjects
- Aged, Aged, 80 and over, Atrial Appendage diagnostic imaging, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Cardiac Catheterization adverse effects, Female, Humans, Ligation, Male, Middle Aged, Pericarditis diagnosis, Pericarditis etiology, Retrospective Studies, Risk Factors, Treatment Outcome, United States, Anti-Inflammatory Agents administration & dosage, Atrial Appendage physiopathology, Atrial Fibrillation therapy, Cardiac Catheterization instrumentation, Colchicine administration & dosage, Pericarditis prevention & control
- Abstract
Introduction: Left atrial appendage (LAA) can be effectively and safely excluded using a novel percutaneous LARIAT ligation system. However, due to pericardial catheter manipulation and LAA ligation and subsequent necrosis, postprocedural course is complicated by pericarditis. We intended to evaluate the preprocedural use of colchicine on the incidence of postprocedural pericardial complications., Methods and Results: In this multicenter observational study, we included all consecutive patients who underwent LARIAT procedure at the participating centers. Many patients received periprocedural colchicine at the discretion of the physician. We compared the postprocedural outcomes of patients who received prophylactic periprocedural colchicine (colchicine group) with those who did not receive colchicine (standard group). A total of 344 consecutive patients, 243 in the "colchicine group" and 101 in the "standard group," were included. The mean age, median CHADS2VASc score, and HASBLED scores were 70 ± 11 years, 3 ± 1.7, and 3 ± 1.1, respectively. There were no significant differences in major baseline characteristics between the two groups. Severe pericarditis was significantly lower in the "colchicine group" compared to the "standard group" (10 [4%] vs. 16 [16%] P<0.0001). The colchicine group, compared to the standard group, had lesser pericardial drain output (186 ± 84 mL vs. 351 ± 83, P<0.001), shorter pericardial drain duration (16 ± 4 vs. 23 ± 19 hours, P<0.04), and similar incidence of delayed pericardial effusion (4 [1.6%] to 3 [3%], P = 0.42) when compared to the standard group., Conclusion: Use of colchicine periprocedurally was associated with significant reduction in postprocedural pericarditis and associated complications., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
15. Evaluation and Treatment of Pericarditis: A Systematic Review.
- Author
-
Imazio M, Gaita F, and LeWinter M
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Chest Pain etiology, Cohort Studies, Colchicine therapeutic use, Humans, Meta-Analysis as Topic, Pericardial Effusion diagnosis, Pericardial Effusion etiology, Prognosis, Randomized Controlled Trials as Topic, Risk Factors, Symptom Assessment methods, Treatment Failure, Pericarditis diagnosis, Pericarditis drug therapy, Pericarditis etiology, Pericarditis mortality, Pericarditis prevention & control
- Abstract
Importance: Pericarditis is the most common form of pericardial disease and a relatively common cause of chest pain., Objective: To summarize published evidence on the causes, diagnosis, therapy, prevention, and prognosis of pericarditis., Evidence Review: A literature search of BioMedCentral, Google Scholar, MEDLINE, Scopus, and the Cochrane Database of Systematic Reviews was performed for human studies without language restriction from January 1, 1990, to August 31, 2015. After literature review and selection of meta-analyses, randomized clinical trials, and large observational studies, 30 studies (5 meta-analyses, 10 randomized clinical trials, and 16 cohort studies) with 7569 adult patients were selected for inclusion., Findings: The etiology of pericarditis may be infectious (eg, viral and bacterial) or noninfectious (eg, systemic inflammatory diseases, cancer, and post-cardiac injury syndromes). Tuberculosis is a major cause of pericarditis in developing countries but accounts for less than 5% of cases in developed countries, where idiopathic, presumed viral causes are responsible for 80% to 90% of cases. The diagnosis is based on clinical criteria including chest pain, a pericardial rub, electrocardiographic changes, and pericardial effusion. Certain features at presentation (temperature >38°C [>100.4°F], subacute course, large effusion or tamponade, and failure of nonsteroidal anti-inflammatory drug [NSAID] treatment) indicate a poorer prognosis and identify patients requiring hospital admission. The most common treatment for idiopathic and viral pericarditis in North America and Europe is NSAID therapy. Adjunctive colchicine can ameliorate the initial episode and is associated with approximately 50% lower recurrence rates. Corticosteroids are a second-line therapy for those who do not respond, are intolerant, or have contraindications to NSAIDs and colchicine. Recurrences may occur in 30% of patients without preventive therapy., Conclusions and Relevance: Pericarditis is the most common form of pericardial disease worldwide and may recur in as many as one-third of patients who present with idiopathic or viral pericarditis. Appropriate triage and treatment with NSAIDs may reduce readmission rates for pericarditis. Treatment with colchicine can reduce recurrence rates.
- Published
- 2015
- Full Text
- View/download PDF
16. Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data.
- Author
-
Agarwal SK, Vallurupalli S, Uretsky BF, and Hakeem A
- Subjects
- Anti-Inflammatory Agents, Humans, Recurrence, Treatment Outcome, Tubulin Modulators administration & dosage, Colchicine administration & dosage, Pericardiectomy, Pericarditis prevention & control, Postpericardiotomy Syndrome prevention & control, Randomized Controlled Trials as Topic, Secondary Prevention methods
- Abstract
The aim of this study is to assess the safety and efficacy of colchicine in prevention of recurrence, symptom reduction, and complications in patients with pericarditis. Pericarditis is an important cause of chest pain leading to frequent emergency room visits and reduced quality of life. Pericarditis has traditionally been treated symptomatically with anti-inflammatory drugs, but growing evidence suggests the use of colchicine for both first episode and recurrent pericarditis in the prevention of recurrences and reducing symptoms. PubMed, EMBASE, and the Cochrane Central register of controlled trials (CENTRAL) databases were searched and the studies were selected using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. All randomized clinical trials with head-to-head comparison between colchicine and standard of care were included. A total of five studies were included in the primary analysis of pericarditis and three in the analysis for prevention of post-pericardiotomy syndrome (PPS). Colchicine reduced the incidence rate of recurrent pericarditis in patients with both the first episode and recurrent pericarditis, compared with placebo [16.7 vs. 36.8%; risk ratio (RR) 0.46; 95% confidence interval (CI) 0.36-0.58; P < 0.00001; I(2) = 0%], with a significant increase in adverse effects (12.5 vs. 8.5%, RR 1.45; 95% CI 1.09-1.95; P = 0.01; I(2) = 0%) and drug withdrawal rate (10.8 vs. 8.5%; RR 1.44; 95% CI 1.01-2.05; P = 0.04; I(2) = 14%). In addition, colchicine decreased symptom duration in patients with recurrent pericarditis (63.1 vs. 78.6%; RR 0.58; 95% CI 0.39-0.87; P = 0.02; I(2) = 65%), but had no significant effect on symptom duration in patients with an initial episode of pericarditis (RR 0.91; 95% CI 0.65-1.28; P = 0.57; I(2) = 0%). Colchicine was superior to placebo in the prevention of PPS at 1 year (13.2 vs. 25.8%, RR 0.56, 95% CI 0.42-0.76; P < 0.01). In this quantitative analysis of randomized clinical data, colchicine demonstrated superior clinical efficacy compared with standard therapy for the prevention of recurrent pericarditis and PPS at the cost of a small increase in the incidence rate of side effects., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
17. What we do not know about the role of colchicine in pericarditis in 2014.
- Author
-
Chhabra L
- Subjects
- Humans, Colchicine therapeutic use, Pericarditis prevention & control, Primary Prevention methods, Secondary Prevention methods
- Published
- 2015
- Full Text
- View/download PDF
18. Prevention of pericarditis with colchicine: an updated meta-analysis.
- Author
-
Briasoulis A and Afonso L
- Subjects
- Humans, Colchicine therapeutic use, Pericarditis prevention & control, Primary Prevention methods, Secondary Prevention methods
- Published
- 2015
- Full Text
- View/download PDF
19. [Internal medicine in the hospital setting].
- Author
-
Moret M, Darbellay P, Lebowitz D, Alves C, Sabeh N, and Carballo S
- Subjects
- Adrenergic beta-Antagonists adverse effects, Aminobutyrates therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Asymptomatic Diseases, Atrial Fibrillation complications, Biphenyl Compounds, Carotid Stenosis diagnosis, Colchicine therapeutic use, Diuretics therapeutic use, Drug Combinations, Heart Failure drug therapy, Hospitals, Humans, Liver Cirrhosis complications, Narcotics therapeutic use, Neprilysin antagonists & inhibitors, Pericarditis prevention & control, Peritonitis complications, Pulmonary Disease, Chronic Obstructive drug therapy, Pulmonary Disease, Chronic Obstructive therapy, Respiratory Therapy, Spironolactone therapeutic use, Stroke etiology, Tetrazoles therapeutic use, Valsartan, Internal Medicine trends
- Abstract
Management of all pathologies, and in particular that of the most frequent ones, should whenever possible be based on robust evidence and arguments. New studies published this year enable rationalizing of screening in certain clinical situations, more adequate treatment of others, and open the way for novel and apparently very effective treatments. Whether it be the screening of carotid stenosis, the treatment of pericarditis, of heart failure, of chronic obstructive lung disease or spontaneous bacterial peritonitis, paradigm changes are conceivable. This selective review of the literature summarizes certain studies published this year.
- Published
- 2015
20. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.
- Author
-
Imazio M, Brucato A, Belli R, Forno D, Ferro S, Trinchero R, and Adler Y
- Subjects
- Chi-Square Distribution, Colchicine adverse effects, Humans, Odds Ratio, Recurrence, Risk Factors, Treatment Outcome, Colchicine therapeutic use, Pericarditis prevention & control, Primary Prevention methods, Secondary Prevention methods
- Abstract
Aims: The purpose of this study was to investigate and summarize available evidence on the efficacy and safety of colchicine for pericarditis prevention. Disease recurrence is the major and most common complication of pericarditis and its prevention may reduce morbidity and management costs. Colchicine has been intensively studied in the last decade for pericarditis prevention., Methods: Controlled clinical studies were searched in several databases and were included provided they focused on the pharmacologic primary or secondary prevention of pericarditis. We performed a meta-analysis including studies of primary outcome, adverse events and drug withdrawal., Results: From the initial sample of 175 citations, seven controlled clinical trials were finally included (1275 patients): five studies were double-blind randomized controlled trials (RCT), and two studies were open-label RCTs. Trials followed patients for a mean of 19 months. Meta-analytic pooling showed that colchicine use was associated with a reduced risk of pericarditis during follow-up [odds ratio (OR) 0.33 (0.25-0.44), P for effect <0.001, P for heterogeneity 0.98, I = 0%] either for primary or secondary prevention without a significant higher risk of adverse events [OR 1.28 (0.84-1.93), P for effect = 0.25, P for heterogeneity = 0.72, I = 0%], and drug withdrawals compared with placebo [OR 1.54 (0.98-2.41), P for effect = 0.06, P for heterogeneity = 0.54, I = 0%]. Gastrointestinal intolerance is the most frequent side-effect (mean incidence 8%), but no severe adverse events were recorded., Conclusion: Colchicine is well tolerated and efficacious for the primary and secondary prevention of pericarditis without a significant increase of the risk of side-effects and drug withdrawals.
- Published
- 2014
- Full Text
- View/download PDF
21. Colchicine for pericarditis.
- Author
-
Chhabra L and Spodick DH
- Subjects
- Humans, Colchicine adverse effects, Colchicine therapeutic use, Gout Suppressants adverse effects, Gout Suppressants therapeutic use, Pericarditis prevention & control
- Published
- 2014
- Full Text
- View/download PDF
22. Response to Letter by Chhabra and Spodick regarding article, "Influence of steroid therapy on the incidence of pericarditis and atrial fibrillation following percutaneous epicardial mapping and ablation for ventricular tachycardia" by Dyrda et al.
- Author
-
Dyrda K, Piers SR, van Huls van Taxis CF, Schalij MJ, and Zeppenfeld K
- Subjects
- Female, Humans, Male, Anti-Inflammatory Agents administration & dosage, Atrial Fibrillation prevention & control, Catheter Ablation adverse effects, Epicardial Mapping adverse effects, Pericarditis prevention & control, Steroids administration & dosage, Tachycardia, Ventricular surgery
- Published
- 2014
- Full Text
- View/download PDF
23. Post cardiac injury syndrome after initially uncomplicated CRT-D implantation: a case report and a systematic review.
- Author
-
Sedaghat-Hamedani F, Zitron E, Kayvanpour E, Lorenz HM, Katus HA, and Meder B
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Heart Injuries diagnosis, Heart Injuries prevention & control, Humans, Male, Middle Aged, Pericardial Effusion diagnosis, Pericardial Effusion prevention & control, Pericarditis diagnosis, Pericarditis prevention & control, Syndrome, Treatment Outcome, Young Adult, Cardiac Resynchronization Therapy Devices adverse effects, Heart Injuries etiology, Pericardial Effusion etiology, Pericarditis etiology, Prosthesis Implantation adverse effects
- Abstract
Background: Post cardiac injury syndrome (PCIS) is an inflammatory process that occurs in the setting of injury to the pericardium, epicardium or myocardium. It may follow cardiac surgery, myocardial infarction, trauma, intracardiac ablation, percutaneous coronary intervention or implantation of a pacemaker or cardioverter-defibrillator., Methods: In this paper, we report the first case of PCIS after implantation of a "Cardiac Resynchronization Therapy Defibrillator" (CRT-D) device and review systematically the available literature. To obtain information on PCIS after implantation of heart rhythm devices (HRD), we performed a systematic review of Medline, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL). The collected data included age, gender, initial diagnosis, procedure type, time to PCIS, symptoms, clinical manifestations, therapy and outcome. Included were reports in English, French and Spanish., Results: In our systematic review, we found PCIS after HRD implantation in 17 additional cases. The age ranged from 23 to 84 years. Symptoms developed within 1 day-4 months after implantation. The use of active-fixation atrial leads was reported in nine cases. Fever, dyspnoea, chest pain, tachypnoea, tachycardia, palpitation, malaise, ankle edema, dry cough, night sweats, nausea and vomiting were reported as associated symptoms., Conclusion: PCIS should be considered as a rare, but serious complication of HRD implantation, may cause recurrent hospitalization and can be life threatening. The incidence and possible causes of PCIS after HRD, such as active fixation leads and specific lead positions as well as its treatment deserve further investigation in prospective studies.
- Published
- 2014
- Full Text
- View/download PDF
24. Letter by Chhabra and Spodick regarding article, "Influence of steroid therapy on the incidence of pericarditis and atrial fibrillation after percutaneous epicardial mapping and ablation for ventricular tachycardia" by Dyrda et al.
- Author
-
Chhabra L and Spodick DH
- Subjects
- Female, Humans, Male, Anti-Inflammatory Agents administration & dosage, Atrial Fibrillation prevention & control, Catheter Ablation adverse effects, Epicardial Mapping adverse effects, Pericarditis prevention & control, Steroids administration & dosage, Tachycardia, Ventricular surgery
- Published
- 2014
- Full Text
- View/download PDF
25. Safety and efficacy of colchicine therapy in the prevention of recurrent pericarditis.
- Author
-
Eun J and Smith A
- Subjects
- Acute Disease, Humans, Pericarditis complications, Recurrence, Colchicine adverse effects, Colchicine therapeutic use, Gout Suppressants adverse effects, Gout Suppressants therapeutic use, Pericarditis prevention & control
- Abstract
Purpose: A review of published data on the safety and efficacy of colchicine therapy for primary and secondary prevention of pericarditis is presented., Summary: Colchicine has been used effectively as an antiinflammatory agent for gout and has shown promise as a treatment for acute and recurrent pericarditis. Several small studies have indicated that colchicine can decrease pericarditis symptom persistence at 72 hours and pericarditis recurrence rates at 18 months compared with conventional therapy (corticosteroids and aspirin or ibuprofen). A review of pooled data from four prospective randomized trials concluded that colchicine is safe and efficacious for the management of acute and recurrent pericarditis, with the results indicating lower rates of the respective primary and secondary endpoints of recurrent disease and symptom persistence in colchicine-treated patients. A separate meta-analysis of five studies found a reduced risk of pericarditis with colchicine use, suggesting that the drug may have clinical utility in both primary and secondary prevention. The accumulated evidence suggests that treatment with colchicine in the context of pericarditis is safe and well tolerated, with gastrointestinal intolerance being the most common adverse event documented in the clinical trials to date., Conclusion: Based on a review of the literature, prevention of recurrent pericarditis with colchicine can be considered a safe and effective option, though some patients have experienced gastrointestinal intolerance. Due to evidence that corticosteroids may potentially exacerbate the risk of relapse, colchicine may be a safer and preferable option., (Copyright © 2014 by the American Society of Health-System Pharmacists, Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
26. Influence of steroid therapy on the incidence of pericarditis and atrial fibrillation after percutaneous epicardial mapping and ablation for ventricular tachycardia.
- Author
-
Dyrda K, Piers SR, van Huls van Taxis CF, Schalij MJ, and Zeppenfeld K
- Subjects
- Administration, Intravenous, Administration, Oral, Adult, Aged, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Chest Pain epidemiology, Chest Pain prevention & control, Electrocardiography, Female, Humans, Incidence, Male, Middle Aged, Pericarditis diagnosis, Pericarditis epidemiology, Predictive Value of Tests, Retrospective Studies, Risk Factors, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular epidemiology, Time Factors, Treatment Outcome, Anti-Inflammatory Agents administration & dosage, Atrial Fibrillation prevention & control, Catheter Ablation adverse effects, Epicardial Mapping adverse effects, Pericarditis prevention & control, Steroids administration & dosage, Tachycardia, Ventricular surgery
- Abstract
Background: This study evaluates the influence of 3 therapeutic approaches on the incidence of pericarditis and atrial fibrillation (AF) after percutaneous epicardial mapping and ablation for ventricular tachycardia., Methods and Results: Eighty-five consecutive procedures (2006-2011) were retrospectively reviewed. After the first 17 procedures (20.0%), no steroids were administered. For the subsequent 30 procedures (35.3%), systemic steroids were administered intravenously or orally, whereas the last 38 procedures (44.7%) were followed by intrapericardial steroid injection. Compared with no steroids, the incidence of pericarditic chest pain was significantly reduced by intrapericardial steroids (58.8% versus 21.1%; P=0.006) but not by intravenous or oral steroids (58.8% versus 43.4%; P=0.31). There was no significant difference in the incidence of pericarditic ECG with steroids (36.8%, 30.0%, and 41.2% for intrapericardial, intravenous or oral, and none, respectively). There was a nonsignificant reduced incidence of chest pain with ECG changes with steroids (13.2%, 10.0%, and 29.4% for intrapericardial, intravenous or oral, and none, respectively). Radiofrequency applications (65.9% of procedures) did not affect the incidence of pericarditic ECG changes, pericarditic chest pain, or pericarditis (all P>0.05). In 7 (8.3%) patients with no prior history of AF, AF was documented a median 36 hours after procedure. Patients with pericarditic ECG tended to be at greater risk of AF (16.7 versus 3.6%; P=0.091)., Conclusions: There is a high incidence of pericarditic chest pain and ECG changes after epicardial ventricular tachycardia mapping and ablation. Pericarditic chest pain is significantly decreased by intrapericardial steroids. Procedure-related AF is relatively frequent and tends to occur more commonly with pericarditic ECG changes., (© 2014 American Heart Association, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
27. CORP-2 trial and the role of colchicine in nonidiopathic pericarditis.
- Author
-
Chhabra L, Dua K, and Spodick DH
- Subjects
- Humans, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Pericarditis prevention & control
- Published
- 2014
- Full Text
- View/download PDF
28. Pharmacotherapy: Colchicine for recurrent pericarditis--what's new in CORP-2?
- Author
-
Syed FF and Mayosi BM
- Subjects
- Humans, Randomized Controlled Trials as Topic, Secondary Prevention, Treatment Outcome, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Pericarditis prevention & control
- Published
- 2014
- Full Text
- View/download PDF
29. Cardiac perforation and lead dislodgement after implantation of a MR-conditional pacing lead: a single-center experience.
- Author
-
Elmouchi DA, Rosema S, Vanoosterhout SM, Khan M, Davis AT, Gauri AJ, Finta B, Woelfel AK, and Chalfoun NT
- Subjects
- Aged, Equipment Failure, Equipment Safety, Female, Foreign-Body Migration prevention & control, Heart Injuries prevention & control, Humans, Magnetic Resonance Imaging adverse effects, Male, Pericarditis etiology, Pericarditis prevention & control, Prosthesis-Related Infections etiology, Prosthesis-Related Infections prevention & control, Retrospective Studies, Survival Rate, Treatment Outcome, Wounds, Penetrating prevention & control, Electrodes, Implanted adverse effects, Foreign-Body Migration etiology, Heart Injuries etiology, Magnetic Resonance Imaging instrumentation, Pacemaker, Artificial adverse effects, Wounds, Penetrating etiology
- Abstract
Objective: The purpose of our study was to determine if the rate of lead-related complications was increased with the Medtronic CapSureFix MRI™ SureScan™ 5086 MRI pacing lead (5086; Medtronic Inc., Minneapolis, MN, USA) compared to the previous generation of Medtronic CapSureFix Novus™ 5076 pacing lead (5076)., Background: The 5086 lead is a newly introduced active-fixation pacemaker lead designed to be used conditionally in a magnetic resonance (MR) scanner. This lead has specific design changes compared to the previous generation of 5076 pacing leads., Methods: This study was a retrospective case control study of 65 consecutive patients implanted with two 5086 leads compared to 92 consecutive control patients implanted with two 5076 leads over a 14-month period at a high-volume tertiary care hospital., Results: Pericarditis, pericardial effusion, cardiac tamponade, or death within 30 days of implant were seen in eight patients from the 5086 cohort and two from the 5076 cohort (odds ratio 6.3, 95% confidence interval 1.3-30.8, P = 0.02). Lead dislodgement occurred in four of the 5086 patients and in none of the 5076 patients (P < 0.03)., Conclusions: In a high-volume center, the incidence of pericarditis, cardiac perforation, tamponade, death, and lead dislodgement was significantly higher with the MR-conditional Medtronic 5086 lead when compared to the previous generation Medtronic 5076 lead., (©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
30. Scedosporium prolificans pericarditis and mycotic aortic aneurysm in a lung transplant recipient receiving voriconazole prophylaxis.
- Author
-
Sayah DM, Schwartz BS, Kukreja J, Singer JP, Golden JA, and Leard LE
- Subjects
- Aged, Aneurysm, Infected diagnosis, Aneurysm, Infected prevention & control, Antifungal Agents therapeutic use, Aortic Aneurysm diagnosis, Aortic Aneurysm prevention & control, Drug Resistance, Fungal drug effects, Female, Humans, Mycoses diagnosis, Mycoses prevention & control, Pericarditis diagnosis, Pericarditis prevention & control, Voriconazole, Aneurysm, Infected microbiology, Aortic Aneurysm microbiology, Lung Transplantation, Mycoses microbiology, Pericarditis microbiology, Pyrimidines therapeutic use, Scedosporium isolation & purification, Triazoles therapeutic use
- Abstract
Despite the adoption of antifungal prophylaxis, fungal infections remain a significant concern in lung transplant recipients. Indeed, some concern exists that such prophylaxis may increase the risk of infection with drug-resistant fungal organisms. Here, we describe a case of disseminated Scedosporium prolificans infection, presenting as pericarditis, which developed in a lung transplant patient receiving prophylactic voriconazole for 8 months. The epidemiology and clinical presentation of S. prolificans infections are reviewed, and controversies surrounding antifungal prophylaxis and the development of resistant infections are discussed., (© 2013 John Wiley & Sons A/S.)
- Published
- 2013
- Full Text
- View/download PDF
31. A subunit vaccine against hydropericardium syndrome using adenovirus penton capsid protein.
- Author
-
Shah MS, Ashraf A, Rahman M, Khan MI, and Qureshi JA
- Subjects
- Adenoviridae Infections prevention & control, Animals, Capsid Proteins administration & dosage, Escherichia coli genetics, Gene Expression, Pericarditis prevention & control, Poultry, Vaccines, Subunit administration & dosage, Vaccines, Subunit immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Viral Vaccines administration & dosage, Adenoviridae Infections veterinary, Capsid Proteins immunology, Pericarditis veterinary, Poultry Diseases prevention & control, Viral Vaccines immunology
- Abstract
Hydropericardium syndrome (HPS) is a disease of poultry that is caused by fowl adenovirus-4. Inactivated liver homogenate from diseased birds is still the choice of vaccine in some countries which disseminates numerous pathogens along with inactivated virus. Moreover incomplete attenuation or inactivation, reversion to virulence and the oncogenic potential/genetic instability of the adenoviruses have prevented their use in routine vaccines. To address this problem an effort is made to develop a subunit vaccine. For this purpose penton base protein of HPS virus was expressed in Escherichia coli and used as subunit vaccine in broilers. Immunogenicity of the recombinant penton base protein and challenge protection test against pathogenic virus demonstrated the ability of recombinant penton base protein to confer (90%) protection. Results suggest that the recombinant penton base protein is a candidate for subunit vaccine against HPS., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
32. Treatment of recurrent pericarditis.
- Author
-
Imazio M
- Subjects
- Anti-Inflammatory Agents adverse effects, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Drug Therapy, Combination adverse effects, Humans, Immunosuppressive Agents adverse effects, Pericarditis diagnosis, Pericarditis immunology, Pericarditis prevention & control, Prognosis, Secondary Prevention, Anti-Inflammatory Agents therapeutic use, Evidence-Based Medicine, Immunosuppressive Agents therapeutic use, Pericarditis drug therapy
- Abstract
Recurrent pericarditis is the most common and troublesome complication of pericarditis affecting around a third of patients. Treatment of this condition is often one of the most challenging task in pericardial diseases management, especially in corticosteroids-dependent cases. The aim of this review is to report current knowledge on the treatment, prevention and prognosis of this disease, with a special focus on more recently published contributions during the last 5 years.
- Published
- 2012
- Full Text
- View/download PDF
33. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis.
- Author
-
Imazio M, Brucato A, Forno D, Ferro S, Belli R, Trinchero R, and Adler Y
- Subjects
- Gout Suppressants therapeutic use, Humans, Colchicine therapeutic use, Pericarditis prevention & control, Secondary Prevention methods
- Abstract
Objectives: The purpose of this study was to investigate the efficacy and safety of colchicine for pericarditis prevention., Background: Recurrent pericarditis prevention is a major management goal that may reduce morbidity and management costs. Although empiric anti-inflammatory therapy is considered the mainstay of treatment, no specific drug has been proven to be efficacious for prevention but colchicine., Methods: Controlled clinical studies were searched in several databases and were included provided they focused on the pharmacologic primary or secondary prevention of pericarditis. We performed a meta-analysis including studies primary outcome, adverse events, and drug withdrawal., Results: From the initial sample of 127 citations, five controlled clinical trials were finally included (795 patients): three studies were double-blind randomised controlled trials, and two studies were open-label randomised controlled trials. Trials followed patients for a mean of 13 months. Meta-analytic pooling showed that colchicine use was associated with a reduced risk of pericarditis during follow-up (RR=0.40, 95% CI 0.30 to 0.54, p for effect <0.001, p for heterogeneity = 0.95, I(2)=0%) either for primary or secondary prevention without a significant higher risk of adverse events compared with placebo (RR=1.22, 95% CI 0.71 to 2.10, p for effect 0.48, p for heterogeneity = 0.44, I(2)=0%), but more cases of drug withdrawals (RR=1.85, 95% CI 1.04 to 3.29, p for effect 0.04, p for heterogeneity = 0.42, I(2)=0%). Gastrointestinal intolerance is the most frequent side effect (mean incidence 8%), but no severe adverse events were recorded., Conclusions: Available evidence suggests that colchicine is safe and efficacious for the primary and secondary prevention of pericarditis.
- Published
- 2012
- Full Text
- View/download PDF
34. 84-year-old woman with chest pain.
- Author
-
Hardegree EL and Bell MR
- Subjects
- Acute Disease, Aged, 80 and over, Arthritis, Rheumatoid complications, Causality, Coronary Angiography, Diagnosis, Differential, Diagnostic Errors, Echocardiography, Electrocardiography, Female, Humans, Myocardial Infarction physiopathology, Pericarditis diagnostic imaging, Pericarditis physiopathology, Pericarditis prevention & control, Chest Pain etiology, Coronary Artery Disease diagnostic imaging, Heart Conduction System physiopathology, Myocardial Infarction diagnosis, Pericarditis diagnosis
- Published
- 2012
- Full Text
- View/download PDF
35. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function.
- Author
-
Abston ED, Barin JG, Cihakova D, Bucek A, Coronado MJ, Brandt JE, Bedja D, Kim JB, Georgakopoulos D, Gabrielson KL, Mitzner W, and Fairweather D
- Subjects
- Animals, Autoimmune Diseases etiology, Autoimmune Diseases prevention & control, Autoimmune Diseases virology, Cardiomyopathy, Dilated metabolism, Coxsackievirus Infections complications, Disease Models, Animal, Eosinophilia prevention & control, Eosinophilia virology, Heart drug effects, Interleukin-1 Receptor-Like 1 Protein, Interleukin-1beta deficiency, Interleukin-1beta genetics, Interleukin-1beta metabolism, Interleukin-33, Interleukin-6 deficiency, Interleukin-6 genetics, Interleukin-6 metabolism, Interleukins pharmacology, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Myocardium metabolism, Pericarditis prevention & control, Pericarditis virology, Recombinant Proteins adverse effects, Recombinant Proteins pharmacology, Recombinant Proteins therapeutic use, Cardiomyopathy, Dilated etiology, Cardiomyopathy, Dilated prevention & control, Eosinophilia etiology, Heart physiopathology, Interleukins adverse effects, Pericarditis etiology, Receptors, Interleukin therapeutic use
- Abstract
Background: IL-33 through its receptor ST2 protects the heart from myocardial infarct and hypertrophy in animal models but, paradoxically, increases autoimmune disease. In this study, we examined the effect of IL-33 or ST2 administration on autoimmune heart disease., Methods and Results: We used pressure-volume relationships and isoproterenol challenge to assess the effect of recombinant (r) IL-33 or rST2 (eg, soluble ST2) administration on the development of autoimmune coxsackievirus B3 myocarditis and dilated cardiomyopathy in male BALB/c mice. The rIL-33 treatment significantly increased acute perimyocarditis (P=0.006) and eosinophilia (P=1.3×10(-5)), impaired cardiac function (maximum ventricular power, P=0.0002), and increased ventricular dilation (end-diastolic volume, P=0.01). The rST2 treatment prevented eosinophilia and improved heart function compared with rIL-33 treatment (ejection fraction, P=0.009). Neither treatment altered viral replication. The rIL-33 treatment increased IL-4, IL-33, IL-1β, and IL-6 levels in the heart during acute myocarditis. To determine whether IL-33 altered cardiac function on its own, we administered rIL-33 to undiseased mice and found that rIL-33 induced eosinophilic pericarditis and adversely affected heart function. We used cytokine knockout mice to determine that this effect was due to IL-33-mediated signaling but not to IL-1β or IL-6., Conclusions: We show for the first time to our knowledge that IL-33 induces eosinophilic pericarditis, whereas soluble ST2 prevents eosinophilia and improves systolic function, and that IL-33 independently adversely affects heart function through the IL-33 receptor.
- Published
- 2012
- Full Text
- View/download PDF
36. Effect of SDS-based decelullarization in the prevention of calcification in glutaraldehyde-preserved bovine pericardium: study in rats.
- Author
-
Collatusso C, Roderjan JG, Vieira ED, Costa FD, Noronha Ld, and Fornazari Dde F
- Subjects
- Animals, Calcinosis pathology, Cattle, Fixatives pharmacology, Glutaral pharmacology, Models, Animal, Organ Preservation methods, Pericarditis prevention & control, Pericardium pathology, Pericardium transplantation, Random Allocation, Rats, Rats, Sprague-Dawley, Statistics, Nonparametric, Subcutaneous Tissue, Tissue Fixation methods, Bioprosthesis, Calcinosis prevention & control, Heart Valve Prosthesis, Pericardium drug effects, Sodium Dodecyl Sulfate pharmacology, Tissue Engineering methods
- Abstract
Objective: The aim of study was to investigate the SDS-based decellularization process as an anticalcification method in glutaraldehyde-preserved bovine pericardium in subcutaneous rat model., Methods: Pericardium samples with 0.5 cm² area were divide in four groups: group GDA: 0.5% glutaraldehyde-preserved pericardium (GDA); group GDA-GL: GDA + 0.2% glutamic acid (GL); group D-GDA: decellularized (D) pericardium with 0.1% SDS + GDA and group D-GDA-GL: decellularized pericardium + GDA + 0.2% glutamic acid. After this samples were implanted in 18 rats in subcutaneous position till 90 days. Each animal received samples of the four groups. The explants were performed at 45 and 90 days. The explants were subjected to histology in glass slides stained with hematoxilin-eosin and alizarin red, morphometry evaluation and the calcium content was measured by flame atomic absorption spectrometry., Results: The inflammatory infiltrate was the same in all groups, however more intense in GDA and GDA-GL groups in 45 days, increasing at 90 days. The calcium contents for 45 days were: 32.52 ± 3.19 µg/mg in GDA group; 22.12 ± 3.87 µg/ mg in GDA-GL group; 1.06 ± 0.38 µg/mg in D-GDA group and 3.99 ± 5.78 µg/mg in D-GDA-GL (P< 0.001). For 90 days were 65.91 ± 24.67 µg/mg in GDA group; 38.37 ± 13.79 µg/mg in GDA-GL group; 1.24 ± 0.99 µg/mg in D-GDA group and 30.54 ± 8.21 µg/mg in D-GDA-GL (P< 0.001). Only D-GDA did not show increase rates of calcium at 45 to 90 days (P=0.314)., Conclusion: SDS-based decellularization process reduced the inflammatory intensity and calcification in bovine pericardium in subcutaneous rat model for 90 days.
- Published
- 2012
- Full Text
- View/download PDF
37. n-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
- Author
-
Zhang Z, Zhang C, Wang H, Zhao J, Liu L, Lee J, He Y, and Zheng Q
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Atrial Fibrillation pathology, Dogs, Inflammation pathology, Inflammation prevention & control, Pericarditis pathology, Random Allocation, Atrial Fibrillation prevention & control, Dietary Supplements, Disease Models, Animal, Fatty Acids, Omega-3 therapeutic use, Pericarditis prevention & control
- Abstract
Objective: It has been recently reported that atrial fibrillation (AF) is associated with inflammation and inflammatory cytokines, and n-3 polyunsaturated fatty acids (PUFAs) might be of anti-inflammatory effects. This study was to evaluate the anti-inflammatory effect of PUFAs on AF in a canine sterile pericarditis model., Methods: 20 dogs were randomly assigned to two groups: control group (10 dogs) and PUFA treatment group (10 dogs), in which sterile pericarditis was created by open-chest operation. PUFAs were administered orally (2g/day) 4 weeks before the operation till the end of the study. Before and 2 days after the operation, CRP, IL-6, TNF-α levels, the inducibility and maintenance of AF, the atrial effective refractory period (AERPs), and intra-atrial conduction time were determined., Results: Before the operation, there were no significant differences in any of the parameters between the two groups. On the second postoperative day, the PUFA group had a lower CRP level (7.6 ± 0.5 vs. 11.7 ± 1.3mg/dl, P<0.0001), a lower IL-6 level (112.0 ± 37.3 vs. 142.0 ± 19.6 pg/ml, P<0.01), a lower TNF-α level (83.3 ± 8.5 vs. 112.4 ± 8.2 pg/ml, P<0.0001), a less AF inducibility (percentage of burst attempts leading to AF episodes: 11 ± 7.4 vs. 28 ± 10.3, P<0.001) and maintenance [median AF duration: 1105 s (655.8-1406.5) vs. 2516.5 s (1187-3361), P<0.05], a longer AERP (133.4 ± 4.1 vs. 129.8 ± 4.3 ms, P<0.05), and a shorter intra-atrial conduction time (46.6 ± 4.4 vs. 51.9 ± 4.8 ms, P<0.05) than the control group., Conclusions: Dietary n-3 PUFA supplementation attenuates the inducibility and maintenance of AF in the sterile pericarditis model by reducing the production of proinflammatory cytokines., (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
38. Colchicine for recurrent pericarditis (CORP): a randomized trial.
- Author
-
Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, and Adler Y
- Subjects
- Adult, Anti-Inflammatory Agents adverse effects, Colchicine adverse effects, Double-Blind Method, Female, Humans, Male, Middle Aged, Pericarditis prevention & control, Prospective Studies, Secondary Prevention, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Pericarditis drug therapy
- Abstract
Background: Recurrence is the most common complication of pericarditis, affecting 10% to 50% of patients., Objective: To evaluate the efficacy and safety of colchicine for the secondary prevention of recurrent pericarditis., Design: Prospective, randomized, double-blind, placebo-controlled multicenter trial. (ClinicalTrials.gov registration number: NCT00128414) SETTING: 4 general hospitals in urban areas of Italy., Patients: 120 patients with a first recurrence of pericarditis., Intervention: In addition to conventional treatment, patients were randomly assigned to receive either placebo or colchicine, 1.0 to 2.0 mg on the first day followed by a maintenance dose of 0.5 to 1.0 mg/d, for 6 months., Measurements: The primary study end point was the recurrence rate at 18 months. Secondary end points were symptom persistence at 72 hours, remission rate at 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and rate of constrictive pericarditis., Results: At 18 months, the recurrence rate was 24% in the colchicine group and 55% in the placebo group (absolute risk reduction, 0.31 [95% CI, 0.13 to 0.46]; relative risk reduction, 0.56 [CI, 0.27 to 0.73]; number needed to treat, 3 [CI, 2 to 7]). Colchicine reduced the persistence of symptoms at 72 hours (absolute risk reduction, 0.30 [CI, 0.13 to 0.45]; relative risk reduction, 0.56 [CI, 0.27 to 0.74]) and mean number of recurrences, increased the remission rate at 1 week, and prolonged the time to subsequent recurrence. The study groups had similar rates of side effects and drug withdrawal., Limitation: Multiple recurrences and neoplastic or bacterial causes were excluded., Conclusion: Colchicine is safe and effective for secondary prevention of recurrent pericarditis.
- Published
- 2011
- Full Text
- View/download PDF
39. Summaries for patients. Colchicine treatment for recurrent pericarditis.
- Subjects
- Anti-Inflammatory Agents adverse effects, Colchicine adverse effects, Humans, Pericarditis prevention & control, Secondary Prevention, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Pericarditis drug therapy
- Published
- 2011
- Full Text
- View/download PDF
40. Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens.
- Author
-
Mansoor MK, Hussain I, Arshad M, and Muhammad G
- Subjects
- Adenoviridae Infections prevention & control, Animals, Antibodies, Viral blood, Chick Embryo, Pericarditis prevention & control, Pericarditis virology, Poultry Diseases virology, Adenoviridae Infections veterinary, Aviadenovirus classification, Chickens, Pericarditis veterinary, Poultry Diseases prevention & control, Viral Vaccines immunology
- Abstract
The current study was planned to develop an efficient vaccine against hydropericardium syndrome virus (HSV). Currently, formalin-inactivated liver organ vaccines failed to protect the Pakistan broiler industry from this destructive disease of economic importance. A field isolate of the pathogenic hydropericardium syndrome virus was adapted to chicken embryos after four blind passages. The chicken embryo-adapted virus was further serially passaged (12 times) to get complete attenuation. Groups of broiler chickens free from maternal antibodies against HSV at the age of 14 days were immunized either with 16th passage attenuated HSV vaccine or commercially formalized liver organ vaccine. The antibody response, measured by enzyme-linked immunosorbent assay was significantly higher (P < 0.05) in the group immunized with the 16th passage attenuated HSV vaccine compared to the group immunized with liver organ vaccine at 7, 14, and 21 days post-immunization. At 24 days of age, the broiler chickens in each group were challenged with 10(3.83) embryo infectious dose(50) of pathogenic HSV and were observed for 7 days post-challenge. Vaccination with the 16th passage attenuated HSV gave 94.73% protection as validated on the basis of clinical signs (5.26%), gross lesions in the liver and heart (5.26%), histopathological lesions in the liver (1.5 ± 0.20), and mortality (5.26%). The birds inoculated with liver organ vaccine showed significantly low (p < 0.05; 55%) protection estimated on the basis of clinical signs (40%), gross lesions in the liver and heart (45%), histopathological lesions in the liver (2.7 ± 0.72), and mortality (35%). Birds in the unvaccinated control group showed high morbidity (84%), mortality (70%), gross (85%), and histopathological lesions (3.79 ± 0.14) with only 10% protection. In conclusion, this newly developed HSV vaccine proved to be immunogenic and has potential for controlling HSV infections in chickens.
- Published
- 2011
- Full Text
- View/download PDF
41. [Posttraumatic pericarditis - the treatment and prophylaxis].
- Author
-
Abakumov MM, Danielian ShN, Radchenko IuA, Popova IE, and Sokolova EP
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Echocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pericarditis diagnosis, Pericarditis etiology, Prognosis, Radiography, Thoracic, Retrospective Studies, Thoracic Injuries diagnosis, Tomography, X-Ray Computed, Young Adult, Anti-Bacterial Agents therapeutic use, Drainage methods, Pericarditis prevention & control, Pericardium injuries, Pleural Cavity surgery, Thoracic Injuries complications
- Abstract
Results of treatment of 100 patients with posttraumatic pericarditis after stab (n=79) and blunt (n=21) thoracic trauma. Factors, leading to pericarditis onset, were primary infection, direct heart and pericardium injury (87,3%), inadequate pericardial cavity drainage (13,9%), insufficient medicamental pericarditis prophylaxis postoperatively (8,9%). Late medical recourse after blunt trauma of the thorax had led to pericarditis onset due to clotted hemothorax (23,8%), exudative pleurisy (19%) and pleural empyema (14,3%). Early diagnose and complex conservative treatment of posttraumatic pericarditis allowed recover in 78,5% (n=62) and 81% (n=17) of patients with stab and blunt thoracic trauma, respectively. Pericardial cavity drainage with intrapericardial streptokinase introduction proved to be an effective method of treatment of fibrinopurulent pericarditis.
- Published
- 2010
42. Colchicine for the primary and secondary prevention of pericarditis: an update.
- Author
-
Kuo If, Pearson GJ, and Koshman SL
- Subjects
- Anti-Inflammatory Agents adverse effects, Anti-Inflammatory Agents pharmacology, Cardiopulmonary Bypass adverse effects, Colchicine adverse effects, Colchicine pharmacology, Humans, Postpericardiotomy Syndrome prevention & control, Primary Prevention methods, Randomized Controlled Trials as Topic, Secondary Prevention methods, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Pericarditis prevention & control
- Abstract
Objective: To review the efficacy and safety of colchicine as primary and secondary prophylaxis for pericarditis., Data Sources: We searched MEDLINE, EMBASE, PubMed, BIOSIS Previews, International Pharmaceutical Abstracts, Web of Science, and CENTRAL for controlled studies from database inception date to July 2009. Search terms included colchicine, pericarditis, and postpericardiotomy syndrome (PPS)., Study Selection and Data Extraction: Prospective, randomized, controlled trials investigating the use of colchicine in preventing pericarditis were included. Data extracted included design, inclusion criteria, demographics, interventions, background therapy, and pericarditis-related clinical outcomes., Data Synthesis: Data were synthesized qualitatively, given variable study designs. Three trials were identified. A single trial examining primary prevention evaluated the use of colchicine versus placebo for preventing PPS in patients undergoing cardiopulmonary bypass grafting. No significant reduction in PPS was found. Two studies examined secondary prevention of pericarditis, comparing colchicine plus aspirin versus aspirin alone. One study examined using these comparators to treat a first episode of pericarditis. After 3 months, there was a significant reduction in recurrent pericarditis with colchicine plus aspirin (11.7% vs 33%; p = 0.009). Another study examined this same regimen in recurrent pericarditis, finding a significant reduction in recurrence after 6 months (21% vs 45%; p = 0.02)., Conclusions: Despite limitations in study designs, current evidence suggests a role for colchicine in the secondary prophylaxis for recurrent pericarditis. The evidence for use of colchicine as primary prophylaxis in PPS is indeterminate; therefore, colchicine cannot be recommended routinely. While colchicine should be recommended for the prevention of recurrent pericarditis, questions regarding the optimal regimen and long-term safety profile need to be further elucidated.
- Published
- 2009
- Full Text
- View/download PDF
43. Nocardia farcinica pericarditis after kidney transplantation despite prophylaxis.
- Author
-
McPhee L, Stogsdill P, and Vella JP
- Subjects
- Antibiotic Prophylaxis, Female, Humans, Middle Aged, Sternotomy, Anti-Infective Agents therapeutic use, Kidney Transplantation adverse effects, Nocardia classification, Nocardia drug effects, Nocardia isolation & purification, Nocardia Infections microbiology, Nocardia Infections prevention & control, Pericarditis microbiology, Pericarditis prevention & control, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use
- Abstract
A deceased-donor kidney transplant recipient developed purulent pericarditis caused by Nocardia despite trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for Pneumocystis jirovecii. She was treated empirically with ceftriaxone and amikacin and subsequently underwent sternotomy with drainage of an intrapericardial abscess. Culture and susceptibility data demonstrated Nocardia farcinica, which was susceptible to SMX and amikacin, although resistant to ceftriaxone. Nocardia asteroides, the more common human pathogen, is generally susceptible to third-generation cephalosporins and TMP-SMX. N. farcinica is rare in the United States, more virulent and resistant than N. asteroides, and is more likely to cause disseminated disease. Successful therapy of disseminated Nocardia infections is dependent upon choice of appropriate empiric antibiotics in addition to surgical drainage of purulent fluid collections. TMP-SMX prophylaxis may not be sufficient to prevent infections due to Nocardia species in all immunosuppressed transplant recipients. Here, a rare complication of this unusual pathogen is discussed.
- Published
- 2009
- Full Text
- View/download PDF
44. Intracoronary stent infection ... Beware the bugs.
- Author
-
Chambers CE
- Subjects
- Aneurysm, Infected prevention & control, Aneurysm, Infected therapy, Aneurysm, Ruptured prevention & control, Aneurysm, Ruptured therapy, Angioplasty, Balloon, Coronary instrumentation, Coronary Aneurysm prevention & control, Coronary Aneurysm therapy, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Humans, Infection Control, Metals, Pericarditis prevention & control, Pericarditis therapy, Prosthesis Design, Prosthesis-Related Infections prevention & control, Prosthesis-Related Infections therapy, Radiography, Staphylococcus aureus isolation & purification, Treatment Outcome, Aneurysm, Infected microbiology, Aneurysm, Ruptured microbiology, Angioplasty, Balloon, Coronary adverse effects, Coronary Aneurysm microbiology, Drug-Eluting Stents adverse effects, Pericarditis microbiology, Prosthesis-Related Infections microbiology, Stents adverse effects
- Published
- 2009
- Full Text
- View/download PDF
45. Delayed pericarditis associated with an implantable cardioverter defibrillator implantation using an active-fixation atrial lead.
- Author
-
Kono K, Todoroki M, Karasawa T, Ito I, Tadokoro K, Shinbo G, Horinaka S, Matsuoka H, and Mochizuki Y
- Subjects
- Heart Atria surgery, Humans, Male, Middle Aged, Pericarditis prevention & control, Prosthesis-Related Infections prevention & control, Defibrillators, Implantable adverse effects, Electrodes, Implanted adverse effects, Pericarditis diagnosis, Pericarditis etiology, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections etiology
- Abstract
A 57-year-old man with nonischemic dilated cardiomyopathy and ventricular tachycardia underwent routine dual chamber implantable cardioverter defibrillator (ICD) implantation. An active-fixation atrial lead was positioned at the lateral wall of the right atrium. He subsequently developed chronic severe pericarditis. Histopathological findings of the pericardium showed mechanical stimulus localized pericarditis. This case demonstrates that contact of the screw of the active-fixation atrial lead with the pericardium may be a possible mechanism for pericarditis after pacemaker/ICD implantation.
- Published
- 2008
- Full Text
- View/download PDF
46. Chemotherapy and cardiotoxicity.
- Author
-
Broder H, Gottlieb RA, and Lepor NE
- Subjects
- Age of Onset, Antibodies, Monoclonal, Humanized, Diagnosis, Differential, Diagnostic Errors prevention & control, Heart Failure, Systolic diagnosis, Heart Failure, Systolic prevention & control, Humans, Neoplasms drug therapy, Pericarditis diagnosis, Pericarditis prevention & control, Time Factors, Trastuzumab, Anthracyclines adverse effects, Antibodies, Monoclonal adverse effects, Antineoplastic Agents adverse effects, Drug Therapy, Drug-Related Side Effects and Adverse Reactions, Fluorouracil adverse effects, Heart Failure, Systolic chemically induced, Pericarditis chemically induced
- Abstract
Newer cancer therapies have improved the survival of patients with cancer and, in some cases, turned cancer into a chronic disease. Patients are now surviving long enough for the adverse cardiovascular effects of some cancer therapies to become apparent. The anthracyclines are perhaps the most notorious offenders. Acute reactions include chest discomfort and shortness of breath consistent with a myopericarditis. Toxicity can also develop months after the last chemotherapy dose and typically presents as new onset heart failure with left ventricular systolic dysfunction. Late reactions are seen years after presentation as new-onset cardiomyopathy, often in patients who were treated for childhood neoplasms. 5-Fluorouracil, its prodrug capecitabine, and trastuzumab, a tumor-specific antibody, have also been associated with cardiotoxicity. Until adequate predictive models, prevention modalities, and treatments can be identified, the clinician's focus should be on aggressive monitoring for early signs of cardiac dysfunction in order to prevent severe systolic dysfunction and its concomitant morbidity and mortality.
- Published
- 2008
47. Experimental efficacy of pericardial instillation of anti-inflammatory agents during percutaneous epicardial catheter ablation to prevent postprocedure pericarditis.
- Author
-
d'Avila A, Neuzil P, Thiagalingam A, Gutierrez P, Aleong R, Ruskin JN, and Reddy VY
- Subjects
- Animals, Catheter Ablation adverse effects, Disease Models, Animal, Instillation, Drug, Pericarditis etiology, Pericarditis pathology, Pericardium, Swine, Treatment Outcome, Triamcinolone administration & dosage, Anti-Inflammatory Agents administration & dosage, Catheter Ablation methods, Pericarditis prevention & control
- Abstract
Introduction: Pericarditis is a potential complication of catheter-based percutaneous epicardial mapping and ablation. This study evaluates the efficacy and safety of intrapericardial instillation of anti-inflammatory agents after pericardial mapping and ablation in a porcine model of postprocedural pericarditis., Methods and Results: Twenty-five healthy swine underwent epicardial mapping and ablation after transthoracic subxyphoid puncture. After 60 minutes of continuous catheter manipulation in the pericardial space, radiofrequency energy was delivered in a linear fashion to the epicardial surfaces of both atria. The animals were randomly divided to receive the anti-inflammatory agents, Hyaluronic Acid and Triamcinolone, or control. Fourteen days after ablation, the hearts were excised and the degree of pericardial reaction/adhesions scored. The severity was uniformly graded 4 (intense) in all control animals and was characterized by intense adhesion between the parietal and the visceral pericardium obscuring tissue planes and epicardial anatomy. Hyaluronic Acid provided a mild benefit (score 3.0 +/- 0.9), but 2 mg/kg of Triamcinolone significantly attenuated the inflammatory effect (all animals uniformly scored 1.0)., Conclusion: In a porcine model of ablation-related pericarditis, intrapericardial instillation of 2 mg/kg of intermediate-acting corticosteroids effectively prevents post-procedure inflammatory adhesion formation.
- Published
- 2007
- Full Text
- View/download PDF
48. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials--two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale.
- Author
-
Imazio M, Cecchi E, Ierna S, and Trinchero R
- Subjects
- Double-Blind Method, Humans, Pericarditis prevention & control, Prospective Studies, Recurrence, Research Design, Colchicine therapeutic use, Pericarditis drug therapy
- Abstract
Background: Colchicine appears to be safe and effective in the treatment and prevention of recurrent pericarditis after failure of conventional therapies in case reports and non-randomized observational studies without control groups. On this basis, colchicine has been proposed as a therapeutic choice in the 2004 guidelines of the European Society of Cardiology. However, the exact number of responders is unknown, and no randomized placebo-controlled trial is available to guide the management of recurrent pericarditis. Moreover, some authors recommend the use of the drug at the first recurrence, whereas others propose to consider the drug only after failure of conventional therapies for the second or subsequent recurrence., Study Design: The CORP trial will enroll 120 patients in a prospective, randomized, double-blind, multicentre investigation of colchicine compared with placebo in patients with a first episode of recurrent pericarditis. In the CORP-2 trial, 240 patients will be enrolled in a prospective, randomized, double-blind, multicentre investigation of colchicine compared with placebo in patients with two or more recurrences. In both trials, the primary efficacy end-point is the recurrence rate at 18 months, the secondary end-points are symptom persistence at 72 h, remission rate at 1 week, number of recurrences, time to recurrence, disease-related hospitalization, cardiac tamponade and constrictive pericarditis., Implications: The CORP and CORP-2 trials will be the first randomized placebo-controlled trials in this area. These trials will provide important evidence regarding the possible benefit of the early use of colchicine for the treatment and prevention of recurrent pericarditis.
- Published
- 2007
- Full Text
- View/download PDF
49. Investigation on Colchicine for Acute Pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design amd rationale.
- Author
-
Imazio M, Cecchi E, Ierna S, and Trinchero R
- Subjects
- Acute Disease, Cardiac Tamponade etiology, Double-Blind Method, Hospitalization, Humans, Italy, Pericarditis complications, Pericarditis, Constrictive etiology, Prospective Studies, Recurrence, Remission Induction, Research Design, Time Factors, Treatment Outcome, Anti-Inflammatory Agents therapeutic use, Colchicine therapeutic use, Pericarditis drug therapy, Pericarditis prevention & control
- Abstract
Background: Colchicine is safe and effective in the treatment and prevention of recurrent pericarditis after failure of conventional treatment. The recent guidelines of the European Society of Cardiology suggest that colchicine might be useful even in the treatment of the first episode. However, the use of the drug is not based on any strong evidence obtained from clinical trials, and no randomized placebo-controlled trial is available to guide the management of acute pericarditis., Study Design: The Investigation on Colchicine for Acute Pericarditis (ICAP) trial will enroll 240 patients in a prospective, randomized, double-blind, multicenter investigation of colchicine compared to placebo in patients with acute pericarditis. The primary efficacy end point is the recurrence rate at 18 months. The secondary end points are symptom persistence at 72 h, remission rate at 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and constrictive pericarditis., Implications: The ICAP trial will be the first randomized placebo-controlled trial in this area. This trial will provide important evidence regarding the possible benefit of the early use of colchicine in the treatment of acute pericarditis and the primary prevention of recurrences, the most troublesome and commonest complication of pericarditis.
- Published
- 2007
- Full Text
- View/download PDF
50. Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis.
- Author
-
Hall SJ and Hickling P
- Subjects
- Adult, Cardiac Tamponade etiology, Etanercept, Humans, Male, Pericarditis etiology, Treatment Failure, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Cardiac Tamponade prevention & control, Immunoglobulin G therapeutic use, Pericarditis prevention & control, Receptors, Tumor Necrosis Factor therapeutic use
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.